Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund
CONCLUSION: Nivolumab as a single agent is fairly active in a cohort of unselected pretreated pleural mesothelioma patients. Further investigations on clinical and translational factors are needed to define which patient might benefit most from nivolumab treatment in pleural mesothelioma.PMID:38372045 | DOI:10.1177/03008916241229287
Source: Tumori - Category: Cancer & Oncology Authors: Luigi Cerbone Sara Delfanti Stefania Crivellari Antonina Maria De Angelis Laura Mazzeo Claudia Proto Mario Occhipinti Giuseppe Lo Russo Chiara Dellepiane Federica Biello Irene Alabiso Francesco Verderame Roberta Gauna Irene De Simone Federica Cuppone Sand Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Immunotherapy | Italy Health | Mesothelioma | Study